REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Target immune therapy enters human trials for aggressive blood cancers
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new type of CAR-T cell therapy designed to attack three different proteins (CD19, CD20, and CD22) found on cancer cells. It is for adults with certain aggressive blood cancers like non-Hodgkin lymphoma, acute lymphob…
Matched conditions: REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Cancer trial aims to slash radiation time and side effects
Disease control Recruiting nowThis study is testing whether a shorter, lower-dose course of radiation therapy works as well as the standard, longer course for treating slow-growing non-Hodgkin lymphoma. The main goal is to see if the shorter treatment causes fewer immediate side effects while still controllin…
Matched conditions: REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC